Multi-targeted tyrosine kinase inhibitor tablets for renal cell carcinoma and thyroid cancer therapies. Acquired by specialized cancer institutes for advanced disease management. Manufactured by oncology-focused pharma companies and distributed to hospital supply chains globally.